T1D and T2D Youth in the Pediatric Diabetes Consortium (PDC) Registries—Comparing Clinical Characteristics and Glycemic Control
TAMBORLANE W, CHENG P, GAL R, KOLLMAN C, VAN NAME M, LYNCH J, NELSON B. T1D and T2D Youth in the Pediatric Diabetes Consortium (PDC) Registries—Comparing Clinical Characteristics and Glycemic Control. Diabetes 2018, 67 DOI: 10.2337/db18-1340-p.Peer-Reviewed Original ResearchTarget HbA1c levelT2D youthHbA1c levelsMedtronic MiniMedResidual endogenous insulin secretionHigher mean HbA1c levelsBoehringer Ingelheim GmbHMean HbA1c levelEndogenous insulin secretionOverweight/obesePoor diabetes outcomesChi-square testMann-Whitney UBoehringer Ingelheim PharmaceuticalsT2D durationClinical characteristicsInsulin therapyGlycemic controlT1D patientsDiabetes careDiabetes outcomesRisk factorsC-peptideInsulin secretionLogistic regressionManagement of Hypertension and Hyperlipidemia in Youth with T2D
BEAULIEU L, CHENG P, KATZ M, LAFFEL L, TAMBORLANE W, VAN NAME M, BANSAL N, KOLLMAN C, GAL R. Management of Hypertension and Hyperlipidemia in Youth with T2D. Diabetes 2018, 67 DOI: 10.2337/db18-1342-p.Peer-Reviewed Original ResearchTreatment of hypertensionBoehringer Ingelheim PharmaceuticalsLifestyle changesMedtronic MiniMedBoehringer Ingelheim GmbHPatient-related barriersManagement of hypertensionUrban academic centerEli LillyAdditional cardiovascular diseaseSelf-reported practicesMannKind CorporationSanofi USCVD complicationsLifestyle modificationGlycemic controlPatient adherenceDiabetes careTreatment recommendationsCardiovascular diseaseHypertensionPatient's perspectiveDiabetes InstituteHyperlipidemiaPhysical activity